866-997-4948 (US-Canada Toll Free)

Cancer Symptoms Partnering 2007-2013

Published By :

Current Partnering

Published Date : 2013-10-08

Category :

Biotechnology

No. of Pages : 150

Product Synopsis

The Cancer Symptoms Partnering 2007-2013 report provides understanding and access to the cancer symptoms partnering deals and agreements entered into by the worlds leading healthcare companies.
 
  • Trends in solid tumor cancer partnering deals
  • Top solid tumor cancer deals by value
  • Deals listed by company A-Z, industry sector, stage of development, technology type
 
The Solid Tumor Cancer Partnering 2007-2013 provides understanding and access to the solid tumor cancer partnering deals and agreements entered into by the worlds leading healthcare companies.
 
This report provides details of thelatest cancer symptoms agreements announced in the healthcare sectors, covering:
 
  • Symptoms
  • Oral mucositis
  • Cancer pain
  • Bone
  • Neuropathic
  • Muscular
  • Lymphoedema
  • Alopecia
  • Cachexia
  • Ulcers
  • Dysphagia
  • Tiredness
  • Weight Loss
  • Nausea
  • Vomiting
  • Chemotherapy
  • Radiotherapy

The report provides an analysis of cancer symptoms partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors cancer symptoms technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
 
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.
 
This data driven report contains over 130 links to online copies of actual cancer symptoms deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
 
The initial chapters of this report provide an orientation of cancer symptoms partnering trends.
 
Chapter 1 provides an introduction to the report, whilst 

Chapter 2 provides an overview of the trends in cancer symptoms partnering since 2007, including a summary of deals by industry sector, stage of development, deal type, and technology type. Numerous tables provide outline financial trends.
 
Chapter 3 provides an overview of the leading cancer symptoms deals since 2007. Deals are listed by headline value, signed by bigpharma, most active of all pharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
 
Chapter 4 provides a comprehensive directory of cancer symptoms partnering deals signed and announced since 2007. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.
 
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of solid tumor cancer technologies and products.
 
Report scope
 
Cancer Symptoms Partnering 2007-2013 is intended to provide the reader with an in-depth understanding and access to cancer symptoms trends and structure of deals entered into by leading companies worldwide.
 
This data driven report includes:
 
  • Trends in cancer symptoms dealmaking in the biopharma industry since 2007
  • Access to summary headline, upfront, milestone and royalty data
  • Access to over 130 cancer symptoms contract documents
  • The leading cancer symptoms deals by value since 2007
 
In Cancer Symptoms Partnering 2007-2013, the available deals are listed by:
 
  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Company A-Z
  • Industry sector
  • Stage of development at signing
  • Deal component type
  • Technology type
 
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Cancer Symptoms Partnering 2007-2013 provides the reader with the following key benefits:
 
  • In-depth understanding of cancer symptoms deal trends since 2007
  • Access to summary headline, upfront, milestone and royalty data
  • Comprehensive access to over 130 actual cancer symptoms deals entered into by the world’s biopharma companies since 2007
  • Insight into key deal terms included in contracts, where disclosed
  • Understand the key deal terms companies have agreed in deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table Of Content

TABLE OF CONTENT

Executive Summary
 
Chapter 1 – Introduction
 
Chapter 2 – Trends in cancer symptoms partnering
2.1. Introduction
2.2. Cancer symptoms partnering over the years
2.3. Bigpharma cancer symptoms dealmaking activity
2.4. Cancer symptoms partnering by deal type
2.5. Cancer symptoms partnering industry sector
2.6. Cancer symptoms partnering by stage of development
2.7. Cancer symptoms partnering by technology type
2.8. Disclosed financial deal terms for cancer symptoms partnering
2.8.1 Cancer symptoms headline values
2.8.2 Cancer symptoms upfront payments
2.8.3 Cancer symptoms milestone payments
2.8.4 Cancer symptoms royalty rates
 
Chapter 3 – Leading cancer symptoms deals
3.1. Introduction
3.2. Top cancer symptoms deals by value
3.3. Top cancer symptoms deals involving bigpharma
 
Chapter 4 – Dealmaking directory
4.1. Introduction
4.2. Company A-Z
4.3. By deal type
Asset purchase
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Contract service
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Manufacturing
Marketing
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Termination
4.4. By industry sector
Academic
Bigpharma
Biotech
Drug delivery
Medical device
Diagnostic
Generic pharma
Government
Non-profit
Pharmaceutical
Research tools
Services
Specialty pharma
4.5. By stage of development
Discovery
Pre-clinical
Phase I
Phase II
Phase III
Registration
Marketed
4.6. By technology type
Analysis
Animal models
Assays
Bioinformatics
Biological compounds
Biomarkers
Biomaterials
Cell culture
Cell therapy
Clinical testing
Diagnostic - companion
Devices
Diagnostics
Discovery tools
DNA probes
Drug delivery
Enabling technology
Epigenetics
Equipment
Facilities
Gene therapy
Genomics
Imaging
Industrial chemicals
In vitro models
Monoclonal antibodies
Nanotechnology
Oligonucleotide
Peptides
Personalised medicine
Processes
Proteomics
Radio/Chemo-therapy
Recombinant DNA
Research services
Research supplies
RNA therapeutics
Screening
Small molecules
Stem cells
Vaccines
 
Chapter 5 – Partnering resource center
5.1. Online partnering
5.2. Partnering events
5.3. Further reading on dealmaking
 
Appendices
 
Appendix 1 – Deal type definitions
 
About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from CurrentPartnering
Order Form – Reports

List of Tables

NA

List of Figures

 
Figure 1: Cancer symptoms partnering since 2007
Figure 2: Bigpharma – top 50 – Cancer symptoms deals 2007 to 2013
Figure 3: Bigpharma cancer symptoms deal frequency – 2007 to 2013
Figure 4: Cancer symptoms partnering by deal type since 2007
Figure 5: Cancer symptoms partnering by industry sector since 2007
Figure 6: Cancer symptoms partnering by stage of development since 2007
Figure 7: Cancer symptoms partnering by technology type since 2007
Figure 8: Cancer symptoms deals with a headline value
Figure 9: Cancer symptoms deals with upfront payment values
Figure 10: Cancer symptoms deals with milestone payments
Figure 11: Cancer symptoms deals with royalty rates, %
Figure 12: Top cancer symptoms deals by value since 2007
Figure 13: Top cancer symptoms deals signed by bigpharma value since 2007
Figure 14: Online partnering resources
Figure 15: Forthcoming partnering events
Figure 16: Deal type definitions

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *

Upcoming Reports

  • Digital Oil Field Technology Market - Global Industry Analysis, Size, Share, Trends, Analysis, Growth And Forecast, 2013 - 2019

    By - Transparency

    Digital oil field technology is the use of automation, instrumentation and IT technologies together in order to improve our existing oil and gas industry technologies. This integration with the help of software makes the analysis much easier and faster. This technology helps in efficient data management, production process optimization, provide more realistic images of the reservoir. Instrumentation and automation includes communication and network processing technologies such as PLC, SCADA, safety system and smart well. Digital oil field technology market can be segmented on the base of...

  • Physician Office Laboratory (POL) Testing Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

    By - Transparency

    Physician office lab (POL) term is wide and diverse, it encompasses physician’s practices as small (2 to 5 doctors) to large practitioners (200 physicians) that operate labs similar to small laboratory hospitals. Hospitals and commercial labs perform tests, but physicians prefer to perform in-house testing in order to enhance the patient care. In-house testing facilitates physicians to no longer rely on the reference labs for test results. In addition, physicians can obtain faster results from their own labs and increase profits. POL also reduces the chances of loss or...

  • Allergic Rhinitis Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019

    By - Transparency

    Allergic Rhinitis is a chronic inflammatory disease of the nasal cavity which causes respiratory problems and affects all age groups. Common symptoms of the disease include sneezing, sore throat, nasal itching and blocked or running nose. The disease often goes unnoticed due to symptoms of the disease coincide with the symptoms of the common cold among humans. Allergic rhinitis can be of three types,such as, perennial, seasonal or both. The allergic rhinitis market can be classified into four major segments based on its treatment, namely, antihistamines, steroids, others and...